Eli Lilly posted a higher fourth-quarter profit Tuesday. The pharmaceutical firm cited lower taxes and better-than-expected drug sales -- especially sales of its newer formulations for diabetes and cancer. (Click for full story.)
The pharma giant maintains an optimistic view, despite omens of a weakening U.S. economy. John Lechleiter, president and chief operating officer -- and Lilly's CEO as of April 1 -- gave CNBC his strong earnings outlook.
- Video: Watch the Entire CEO Interview
"I'm not sure we can claim that our business is recession-proof, completely, but we stand by our guidance of double-digit earnings per share growth between now and 2011, compounded," Eli Lilly President & COO John Lechleiter told CNBC.